|Bid||131.18 x 1100|
|Ask||134.35 x 900|
|Day's Range||129.87 - 131.97|
|52 Week Range||92.56 - 141.86|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||70.30|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.28|
Alexion Pharmaceuticals today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m.
Alexion Pharmaceuticals today announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.m. ET.
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively, in its Q1 2019 Investor Letter. You can download a copy of the letter here. The figures go to show that the fund outperformed both the Russel Value and the S&P […]
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $3.38 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the New England Journal of Medicine (NEJM) published positive data from the Phase 3 PREVENT study of SOLIRIS® (eculizumab), a first-in-class complement inhibitor, in adult patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks. The recommended indication is for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) with haemolysis with clinical symptoms indicative of high disease activity,1 and also for adult patients who are clinically stable2 after having been treated with SOLIRIS® (eculizumab) for at least the past six months.
Alexion Pharmaceuticals beat first-quarter expectations Thursday and raised its 2019 outlook, but sales of treatments for metabolic diseases floundered and continue to be a "sore point."
With a market capitalization of US$30b, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks are their strong balance sheet...
Health-care stocks are being dragged down by fears that a remake of the U.S. health-care system would stunt profits.
On a per-share basis, the Boston-based company said it had profit of $2.61. Earnings, adjusted for one-time gains and costs, came to $2.39 per share. The results beat Wall Street expectations. The average ...